ClinicalTrials.gg
CompletedNCT04997369Updated Nov 20, 2026

Catheterless Water Vapor Therapy for the Treatment of BPH

An interventional study of Rezum in Benign Prostatic Hyperplasia, sponsored by Northwell Health. Completed at 1 site in United States. Open to male participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Northwell Health · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 10 months ago, and no results have been posted to the registry.
Updated Nov 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.

Enrollment
119th of 150
20 · median 83
Started
2021
with 11 others
No phase
63 of 188
13 open now
Registered
138th of 188
by date

Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 119th largest by enrollment of the 150 interventional ones that give a count, is one of 12 that started in 2021, is one of 63 with no phase, and was the 138th registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 40 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Prostatic Hyperplasia with a site in United States, or all of them as a file.
02

Study summary

The Rezum system is an ablative procedure for patients with benign prostatic hyperplasia (BPH). One of the limitations of the technology is the need for post-operative catheterization up to 5 days. The aim of this study is to assess the feasibility of employing Catheterless Rezum post-operatively in patients with normal or strong bladder contractility. Upon a positive outcome of interim analysis, the effectiveness of Catheterless Rezum will be assessed at five sites for the multicenter phase.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

Keywords

  • Water Vapor Therapy
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subject of 40 - 80 years of age
  • Has provided
  • Has a diagnosis of bladder outlet obstruction due to benign prostatic enlargement
  • Able to complete self-administered questionnaires
  • Is a surgical candidate for Rezum
  • Has medical record documentation of Qmax \< 15 ml/s
  • Has medical record documentation of prostate volume from 30-80 ml by transrectal ultrasound (TRUS)
  • Has a bladder contractility index score ≥ 100, calculated by detrusor pressure at Qmax (pDet@qmax) + (5xQmax).
  • Willing to undergo pressure-flow studies to calculate BCI prior to surgical intervention.
  • Has serum creatinine within the normal range.
  • Able to perform intermittent catheterization.

Exclusion criteria

Exclusion Criteria:

  • Has a \< 2 years
  • Is currently enrolled in or plans to enroll in any concurrent drug or device study
  • Has an active infection (e.g., urinary tract infection or prostatitis)
  • Has a diagnosis of or has received treatment for chronic prostatitis or chronic pelvic pain syndrome (e.g., nonbacterial chronic prostatitis)
  • Has been diagnosed with a urethral stricture or bladder neck contracture within the last 180 days
  • Has been diagnosed with 2 or more urethral strictures and/or bladder neck contractures within 5 years
  • Has a diagnosis of lichen sclerosis
  • Has a diagnosis of neurogenic bladder or other neurologic disorder that affects bladder function
  • Has a diagnosis of polyneuropathy (e.g., diabetic)
  • Has a history of lower urinary tract surgery
  • Has a diagnosis of stress urinary incontinence that requires treatment or daily pad or device use
  • Has an inability to perform intermittent self-catheterization
  • Has been catheterized or has a post-void residual (PVR) of > 400 ml in the 14 days prior to the surgical procedure
  • Has a current diagnosis of bladder stones
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Catheterless group

    Device: Rezum

Interventions

  • DeviceRezum

    The Rezum system is an ablative procedure for patients with benign prostatic hyperplasia (BPH).

    Also known as: Water vapor therapy

06

What researchers measure

Primary outcomes

  1. Feasibility of Catheterless Rezum as measured by changes in the International Prostate Symptom Score (IPSS).

    The outcome will be assessed based on a 6.0-point average improvement in the IPSS score. Higher scores indicate greater symptom severity and lower scores indicate less symptom severity.

    Time frame: Baseline, 36 months

  2. Feasibility of Catheterless Rezum as measured by changes in the maximum urinary flow rate (Qmax).

    The outcome will be assessed based on a 2.5-point average improvement in Qmax compared to baseline. Higher Qmax values indicate less urinary obstruction while lower Qmax values correspond to increased urinary obstruction.

    Time frame: Baseline, 36 months

Secondary outcomes

  1. Changes in urinary symptoms as measured by changes in IPSS.

    The outcome will be assessed based on a 6.0-point average improvement in the IPSS score. Higher scores indicate greater symptom severity and lower scores indicate less symptom severity.

    Time frame: Baseline, 36 months

  2. Changes in urinary symptoms as measured by changes in Qmax at 36 months

    The outcome will be assessed based on a 2.5-point average improvement in Qmax compared to baseline. Higher Qmax values indicate less urinary obstruction while lower Qmax values correspond to increased urinary obstruction.

    Time frame: Baseline, 36 months

07

Study locations

1 site
  • Weill Cornell Medicine
    New York, New York 10065, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jan 2024, 27 months.

Of 155 non-industry interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's 27 months is close to that.

Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Jun 2024 → Jan 2024 and completion Jun 2027 → Jun 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Aug 9, 2021
StartActual
Oct 13, 2021
Primary completionActual
Jan 21, 2024was Jun 2024
CompletionActual
Jun 21, 2024was Jun 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Completed Reason for stopping removed
changed Nov 20, 2026
Primary completion
Jun 21, 2024→Jan 21, 2024
Nov 20, 2026
Study completion
Jun 2027→Jun 21, 2024 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Suspended→Completed
    Why stopped Reason for stopping removed
    Primary completion Jun 21, 2024→Jan 21, 2024
    Study completion Jun 2027→Jun 21, 2024 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04997369
Lead sponsor
Northwell Health
Responsible party
Sponsor
First posted
Aug 9, 2021
Start date
Oct 13, 2021
Primary completion
Jan 21, 2024
Completion
Jun 21, 2024
Last update
Nov 20, 2026

Study contacts

Bilal Chughtai, MD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion